The Nordic Model
Norway became the first country to approve national public reimbursement for ketamine treatment. This is how we built the clinical infrastructure that made it possible.
In August 2025, Norway became the first country in the world to approve national public reimbursement for ketamine treatment of depression. This did not happen by accident. It was the result of a decade of clinical practice, research collaboration between private clinics and public hospitals, and careful advocacy within existing regulatory frameworks.
I present the Nordic model as a pragmatic template for psychedelic medicine integration: private innovation establishing safety data, public-private research partnerships building the evidence base, and regulatory dialogue leading to systemic adoption. This is how Norway went from zero ketamine clinics in 2017 to a national treatment programme in 2025.
The talk covers practical lessons for other jurisdictions: what worked, what we would do differently, and what the Swedish expansion in 2026 will test about the model's scalability.
